Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.
PD-L1
high microsatellite instability (MSI-H)
neuroendocrine carcinoma (NEC)
neuroendocrine tumors
next-generation sequencing (NGS)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
09
2021
accepted:
10
01
2022
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Neuroendocrine tumors (NETs) are classified based on morphology and are graded based on their proliferation rate as either well-differentiated low-grade (G1) to intermediate (G2-G3) or poorly differentiated high-grade neuroendocrine carcinomas (NEC G3). Recently, in gastroenteropancreatic (GEP) NETs, a new subgroup of well-differentiated high-grade tumors (NET G3) has been divided from NEC by WHO due to its different clinical-pathologic features. Although several mutational analyses have been performed, a molecular classification of NET is an unmet need in particular for G3, which tends to be more aggressive and have less benefit to the available therapies. Specifically, new possible prognostic and, above all, predictive factors are highly awaited, giving the basis for new treatments. Alteration of
Identifiants
pubmed: 35186729
doi: 10.3389/fonc.2022.780716
pmc: PMC8856722
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
780716Informations de copyright
Copyright © 2022 Prisciandaro, Antista, Raimondi, Corti, Morano, Centonze, Sabella, Mangogna, Randon, Pagani, Prinzi, Niger, Corallo, Castiglioni di Caronno, Massafra, Bartolomeo, Braud, Milione and Pusceddu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cancer. 2016 May 25;7(9):1044-8
pubmed: 27326246
Oncotarget. 2015 Sep 8;6(26):22114-25
pubmed: 26090613
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Mod Pathol. 2013 May;26(5):685-96
pubmed: 23328977
Endocr Relat Cancer. 2018 May;25(5):583-593
pubmed: 29592868
Histopathology. 2014 Jun;64(7):1027-31
pubmed: 24329753
Int J Mol Sci. 2019 Oct 25;20(21):
pubmed: 31731495
Cancer. 2001 Jun 15;91(12):2417-22
pubmed: 11413533
Pancreas. 2010 Aug;39(6):707-12
pubmed: 20664470
Oncotarget. 2017 Apr 7;8(33):54331-54344
pubmed: 28903345
Oncologist. 2016 Jan;21(1):28-32
pubmed: 26659223
Endocr Pathol. 2019 Sep;30(3):237-245
pubmed: 30772928
Anticancer Res. 2014 May;34(5):2249-54
pubmed: 24778027
Onco Targets Ther. 2020 Aug 12;13:8049-8054
pubmed: 32848424
Endocr Relat Cancer. 2016 Sep;23(9):711-26
pubmed: 27353039
Mod Pathol. 2017 Apr;30(4):587-598
pubmed: 28059098
J Pathol. 2017 Mar;241(4):488-500
pubmed: 27873319
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
JAMA Oncol. 2018 Sep 1;4(9):e180077
pubmed: 29566106
Virchows Arch. 2013 Jan;462(1):47-56
pubmed: 23224118
Hum Pathol. 2021 Aug;114:36-43
pubmed: 33891968
Arch Pathol Lab Med. 2011 Dec;135(12):1539-44
pubmed: 22129180
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Neuroendocrinology. 2017;104(1):85-93
pubmed: 26943788
Endocr Relat Cancer. 2017 Sep;24(9):R315-R334
pubmed: 28710117
Oncotarget. 2018 Nov 9;9(88):35809-35812
pubmed: 30533196
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
Medicine (Baltimore). 2015 Dec;94(50):e2224
pubmed: 26683934
Thorac Cancer. 2019 Apr;10(4):839-847
pubmed: 30793508
J Cancer. 2016 Feb 05;7(5):484-9
pubmed: 26958083
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Cancers (Basel). 2020 Sep 24;12(10):
pubmed: 32987854
J Hematol Oncol. 2019 Jun 28;12(1):67
pubmed: 31253167
Cancer Treat Rev. 2017 May;56:28-35
pubmed: 28456055
J Clin Med. 2021 Apr 17;10(8):
pubmed: 33920514
Anticancer Res. 2019 Jan;39(1):413-420
pubmed: 30591488
Histopathology. 2021 Feb;78(3):381-391
pubmed: 32767778
Clin Cancer Res. 2017 Jan 15;23(2):523-535
pubmed: 27440269
EJIFCC. 2019 Jun 24;30(2):146-164
pubmed: 31263390
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
J Thorac Oncol. 2015 Oct;10(10):e104-6
pubmed: 26398829
Neuroendocrinology. 2018;106(1):47-57
pubmed: 28208131
J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040
pubmed: 30181415
Neuroendocrinology. 2021;111(9):883-894
pubmed: 33002892
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Endocr Relat Cancer. 2017 Jun;24(6):R223-R237
pubmed: 28389504
J Pathol. 2021 Jan;253(1):94-105
pubmed: 32985687
Gynecol Oncol. 2021 Jun;161(3):779-786
pubmed: 33888337
Cancer Discov. 2020 Dec;10(12):1808-1825
pubmed: 33139244
Endocr Relat Cancer. 2010 Jun 25;17(3):623-36
pubmed: 20385747
Eur J Gastroenterol Hepatol. 2012 Dec;24(12):1430-7
pubmed: 23114745
J Thorac Oncol. 2010 Aug;5(8):1273-8
pubmed: 20548249
Endocr Pathol. 2021 Jun;32(2):309-317
pubmed: 33409812
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
J Clin Pathol. 2013 Aug;66(8):705-7
pubmed: 23618692
Clin Lung Cancer. 2017 May;18(3):e197-e201
pubmed: 28024928
Am J Surg Pathol. 2001 Nov;25(11):1364-71
pubmed: 11684952
Mod Pathol. 2019 Feb;32(2):290-305
pubmed: 30237525
Endocr Relat Cancer. 2019 Mar 1;26(3):293-301
pubmed: 30608901
Int J Clin Exp Med. 2015 Dec 15;8(12):22149-57
pubmed: 26885189
Gastroenterology. 2012 Dec;143(6):1442-1460.e1
pubmed: 23000599
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Future Oncol. 2021 Mar;17(9):1069-1081
pubmed: 33136448
Neuroendocrinology. 2021;111(5):475-489
pubmed: 32365350
Neuroendocrinology. 2004;80 Suppl 1:3-7
pubmed: 15477707
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
Cancer Cell. 2002 Nov;2(5):367-76
pubmed: 12450792
Endocr Pathol. 2020 Jun;31(2):182-189
pubmed: 32144630
Neuroendocrinology. 2020;110(7-8):616-629
pubmed: 31557757
Genes (Basel). 2014 Jun 27;5(3):497-507
pubmed: 24978665
Int J Cancer. 2019 Mar 15;144(6):1379-1390
pubmed: 30144031
J Thorac Oncol. 2019 Sep;14(9):1651-1661
pubmed: 31085341
Cell Death Dis. 2017 Aug 24;8(8):e3004
pubmed: 28837143
Oncotarget. 2015 Sep 8;6(26):22028-37
pubmed: 26124082
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Clin Cancer Res. 2016 Jul 15;22(14):3618-29
pubmed: 26960398
Oncologist. 2019 Aug;24(8):1076-1088
pubmed: 30635447
Intern Med. 2016;55(21):3151-3153
pubmed: 27803410
Annu Rev Biochem. 2003;72:609-42
pubmed: 12676795
JAMA Netw Open. 2020 Oct 1;3(10):e2025109
pubmed: 33119110
J Thorac Oncol. 2021 Sep;16(9):1570-1581
pubmed: 33823285
Histopathology. 2018 Mar;72(4):707-710
pubmed: 28888040
Clin Cancer Res. 2013 Jul 1;19(13):3600-10
pubmed: 23697990
Pathol Oncol Res. 2020 Oct;26(4):2363-2370
pubmed: 32506394
J Clin Med. 2020 May 13;9(5):
pubmed: 32414120
Ann Oncol. 2016 May;27(5):920-6
pubmed: 26884591
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Oncotarget. 2018 Jun 19;9(47):28379-28390
pubmed: 29983867
Neuroendocrinology. 2015;101(3):246-55
pubmed: 25791280
J Natl Compr Canc Netw. 2011 Dec;9(12):1397-402; quiz 1403
pubmed: 22157557
Endocr Relat Cancer. 2015 Feb;22(1):35-45
pubmed: 25465415
CA Cancer J Clin. 2014 Sep-Oct;64(5):311-36
pubmed: 25104502
Nat Rev Cancer. 2015 Jun;15(6):371-81
pubmed: 25998716
Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):
pubmed: 33608381
Eur Urol Oncol. 2021 Apr;4(2):297-300
pubmed: 32061548
Nat Commun. 2014 Sep 10;5:4846
pubmed: 25204415
Front Oncol. 2020 Jul 17;10:1187
pubmed: 32766159
Clin Colorectal Cancer. 2021 Jun;20(2):177-185.e13
pubmed: 33041225
Clin Cancer Res. 2017 Aug 15;23(16):4625-4632
pubmed: 28455360
Onco Targets Ther. 2018 Aug 17;11:4991-4998
pubmed: 30154667
Oncologist. 2017 Jul;22(7):768-773
pubmed: 28507205
Surg Today. 2007;37(3):270-1
pubmed: 17342373
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Endocr Relat Cancer. 2021 Jan 1;:
pubmed: 33480358
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Transl Lung Cancer Res. 2018 Feb;7(1):50-68
pubmed: 29535912
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Pancreas. 2013 Aug;42(6):949-51
pubmed: 23851431
World J Gastroenterol. 2019 Apr 14;25(14):1684-1696
pubmed: 31011254
J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322
pubmed: 29118225
Oncotarget. 2016 Jul 19;7(29):45462-45478
pubmed: 27323780
Cancer Discov. 2016 Jun;6(6):594-600
pubmed: 27048246
J Pathol Clin Res. 2019 Oct;5(4):217-226
pubmed: 31136102
J Clin Oncol. 2006 Oct 10;24(29):4677-84
pubmed: 16966691
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
EMBO Rep. 2016 Jan;17(1):94-109
pubmed: 26658330
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
Clin Cancer Res. 2020 Sep 15;26(18):4785-4794
pubmed: 32591465
Diagn Pathol. 2019 May 20;14(1):47
pubmed: 31109352
Exp Ther Med. 2011 Nov;2(6):1041-1045
pubmed: 22977617
Clin Cancer Res. 2020 May 15;26(10):2290-2296
pubmed: 31969335
Mol Cancer Res. 2018 May;16(5):805-812
pubmed: 29523759
Intern Med. 2018 Mar 1;57(5):713-716
pubmed: 29151522
Neuroendocrinology. 2018;107(1):73-90
pubmed: 29566385
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068